Core Viewpoint - GDEV Inc. reported a decline in revenue for Q3 2025, primarily due to reduced consumer spending, while achieving a significant increase in profit and adjusted EBITDA compared to the same period in 2024 [3][9]. Financial Performance Summary - Revenue for Q3 2025 was $98 million, a decrease of 12% from $111 million in Q3 2024 [2][9]. - Platform commissions fell by $3 million (13%) to $21 million in Q3 2025 compared to Q3 2024 [4]. - Game operation costs remained stable at $14 million in Q3 2025, slightly up from $13 million in Q3 2024 [4]. - Selling and marketing expenses decreased significantly by 43% to $30 million in Q3 2025 from $52 million in Q3 2024 [5][9]. - General and administrative expenses were stable at $8 million in Q3 2025, compared to $7 million in Q3 2024 [6]. - Profit for the period, net of tax, increased to $24 million in Q3 2025 from $15 million in Q3 2024, marking a 66% increase [7][9]. - Adjusted EBITDA rose to $26 million in Q3 2025, up from $17 million in Q3 2024, representing a 50% increase [7][9]. - Cash flows from operating activities were positive at $15 million in Q3 2025, compared to $12 million in Q3 2024, reflecting a 24% increase [8]. Operational Performance Summary - Total bookings in Q3 2025 were $90 million, down 4% from $93 million in Q3 2024 [10]. - Bookings from in-app purchases decreased by 3% to $85 million in Q3 2025, while bookings from advertising fell by 18% to $5 million [10]. - Monthly paying users (MPU) decreased by 16% to 263,000 in Q3 2025 compared to 314,000 in Q3 2024 [10]. - Average Booking Per Paying User (ABPPU) increased by 16% to $107 in Q3 2025 from $92 in Q3 2024 [10]. - The share of advertising as a percentage of total bookings decreased to 6.0% in Q3 2025 from 7.1% in Q3 2024 [11]. - The split of bookings by platform showed a decrease in mobile share to 59% and an increase in PC share to 41% in Q3 2025 compared to the same period in 2024 [12]. - Geographically, the share of bookings from the US decreased to 32%, while Europe increased to 34% in Q3 2025 compared to Q3 2024 [13].

Core Viewpoint - Kodak introduces two flagship Wi-Fi smart digital frames, the 10.1-inch RWF-109V and the 14.1-inch RWF-141, designed to bridge the gap between digital photos and physical displays, enhancing the way memories are shared and appreciated [1][10]. Product Features - Both models come with 64GB of internal storage, capable of holding tens of thousands of photos, and utilize the Kodak Digital Frame App for real-time sharing and preservation of memories [4][8]. - The smart frames support simultaneous photo and music playback, along with calendar, clock, and weather features, making them multifunctional home centerpieces [5]. - The RWF-141 features a 1920×1080 Full HD display, while the RWF-109V offers a 1920×1200 high-resolution display, providing bright visuals and responsive touch capabilities [6]. - The RWF-141 has a solid wood frame, while the RWF-109V features a selected metal frame, both designed to complement various interior styles [7]. User Experience - The adjustable stand and automatic brightness adjustment enhance usability, making the frames suitable for all ages [6]. - Users can create pre-set greeting cards through the Kodak Digital Frame App, allowing the frames to serve as thoughtful gifts for various occasions [9]. Brand Philosophy - Kodak emphasizes that technology should carry emotions and memories, ensuring that photos are not just stored but actively displayed and cherished in everyday life [2][11].

Core Insights - LB Pharmaceuticals Inc will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 9:30 a.m. ET [1] - A live webcast of the presentation will be available on the Company's website [2] Product Development - LB-102 is a Phase 3-ready oral small molecule and a methylated derivative of amisulpride, showing statistically significant benefits in a Phase 2 trial for acute schizophrenia [3] - The Phase 2 trial demonstrated a potentially class-leading safety profile among D2 antagonists and partial agonists, with positive effects on negative symptoms and cognition [3] - LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression, with potential expansion into major depressive disorder, Alzheimer's disease psychosis, and other conditions [3] Company Overview - LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [4] - The Company aims to leverage the therapeutic potential of LB-102, which could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the U.S. [4] - If approved, LB-102 has the potential to be a mainstay in psychiatric practice, offering an attractive alternative to existing treatments [4]

Core Insights - IP Strategy is the first Nasdaq-listed company to operate a digital asset treasury strategy centered on the $IP token, providing investors with exposure to the programmable intellectual property economy valued at $80 trillion [3] - The company held its inaugural Investor Day 2025, where it discussed its growth strategy and the convergence of AI, blockchain, and intellectual property [2][3] - Story, the blockchain network supporting the $IP token, has received $136 million in backing and launched its mainnet in February 2025, enabling the monetization of intellectual property in real time [5] Company Overview - IP Strategy operates a revenue-generating validator for the Story network and holds $IP tokens as a primary reserve asset [3] - The company aims to provide public market investors with a regulated equity format to participate in the Story ecosystem, which facilitates on-chain registration, licensing, and monetization of intellectual property [3] Industry Context - The Story network is described as an AI-native blockchain that makes intellectual property programmable and traceable, allowing creators to turn various forms of content into legally enforceable digital assets [5] - The convergence of AI, blockchain, and intellectual property is seen as a significant trend shaping a new investable asset class [2]

Atlanta, GA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI), a developer of advanced AI-powered security screening and imaging systems, today announced that it has entered into a non-binding term sheet with ARC Group International Ltd. (“ARC Group”) for a proposed $20 million subordinated convertible note facility financing (the “Proposed Financing”). The Company believes that this prospective financing will complement and operate alongside the Com ...

Core Insights - SEALSQ Corp has appointed Dr. Ballester Lafuente as Chief of Staff and Group AI Officer to enhance the integration of artificial intelligence across its operations and product lines [1][3][8] - Dr. Lafuente's role will focus on driving operational efficiency, innovation, and smarter processes within the company's semiconductor, PKI, IoT, satellite, and post-quantum technology sectors [3][8] - The company aims to leverage Dr. Lafuente's expertise in AI and digital innovation to scale operational excellence and enhance product offerings, positioning itself as a leader in trusted, quantum-resistant digital infrastructures [8][9] Company Overview - SEALSQ specializes in developing and selling semiconductors, PKI, and post-quantum technology hardware and software products [1][9] - The company is pioneering post-quantum semiconductors designed to provide robust protection against quantum computing threats, addressing urgent security challenges in various applications [9][10] - SEALSQ's technology integrates semiconductors with quantum-resistant cryptography, ensuring organizations remain secure against evolving quantum threats [10] Leadership Background - Dr. Ballester Lafuente previously served as Head of IT Innovation at IMD, where he led technology innovation strategy and AI platforms [4] - His experience includes roles at the EPFL Center for Digital Trust and co-founding MobileThinking SARL, focusing on digital trust and cybersecurity initiatives [5][6] - Dr. Lafuente holds advanced degrees in Management Information Systems, Security and Mobile Computing, and Computer Science, equipping him with a strong foundation for his new role [7]

Core Viewpoint - Akebia Therapeutics, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to addressing kidney disease [1][2]. Company Overview - Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals affected by kidney disease, founded in 2007 and headquartered in Cambridge, Massachusetts [3]. - The company is fully integrated, indicating a comprehensive approach to its biopharmaceutical endeavors [3]. Event Details - The Fireside Chat featuring Akebia's executive team is scheduled for December 2, 2025, at 4:30 PM EST [1]. - The Piper Sandler Healthcare Conference will occur from December 2-4, 2025, in New York City [2]. - A webcast of the presentation will be available on Akebia's website under the "Investors" section [2].

Second 50 MW Phase Delivered on Time, Bringing Energized Capacity to 100 MW and Advancing Applied Digital’s AI Factory Campus Toward 400 MWDALLAS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD) today announced the successful and on-time Ready for Service (RFS) for the second phase (50 MW) at the first 100 megawatt (MW) building at Building 1 of its Polaris Forge 1 AI Factory Campus in Ellendale, North Dakota. After achieving this milestone, Building 1 now operates at its full 100 MW critic ...

Core Viewpoint - American Rebel Holdings, Inc. has successfully met the Nasdaq Listing Rule 5550(b)(1) by achieving stockholders' equity of $3,378,257, thus remaining compliant and listed on The Nasdaq Capital Market [1][2]. Compliance Confirmation - The Nasdaq Hearings Panel confirmed compliance on November 21, 2025, following the Company's filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2025 [2][5]. - The compliance determination was based on the Company's stockholders' equity exceeding the required $2.5 million threshold [2][5]. CEO Commentary - The CEO of American Rebel expressed that the compliance notice is a significant milestone for the Company and its stockholders, emphasizing the importance of a Nasdaq listing for liquidity and investor base expansion [3]. - The CEO acknowledged the support from Nasdaq, strategic partners, and stockholders during the compliance process, indicating a focus on long-term value creation moving forward [3]. Monitoring Period - Following the compliance confirmation, the Company will enter a mandatory one-year monitoring period, during which any future non-compliance will lead to immediate delisting without additional cure periods [5][6]. Improvement in Stockholders' Equity - The Company has shown significant improvement in stockholders' equity, moving from a deficit of approximately $(8.0) million as of March 31, 2025, to a positive equity of $3,378,257 by September 30, 2025, reflecting an improvement of roughly $11.4 million [11]. - This improvement is attributed to a series of strategic initiatives executed throughout 2025 to strengthen the balance sheet [7][8]. Company Overview - American Rebel Holdings, Inc. is a patriotic lifestyle brand that has expanded from designing and marketing branded safes to include products like American Rebel Light Beer, apparel, and accessories [9]. - The Company aims to grow within the premium light lager segment across the United States, leveraging experienced distribution partners [9].

Core Insights - NANO Nuclear Energy Inc. has signed a Feasibility Study Agreement with BaRupOn LLC to evaluate the deployment of multiple KRONOS MMR units to generate 1 GW of nuclear energy at the Liberty American Multi-Sourced Power and Innovation Hub in Texas [1][3][4] - The feasibility study will assess power demand, reactor integration, and site suitability for the KRONOS MMR units [2][6] - BaRupOn anticipates a significant power squeeze due to increasing compute demand, particularly from the tech industry, and is willing to co-invest in the construction of NANO Nuclear's microreactors [3][4] Company Overview - NANO Nuclear is focused on developing advanced nuclear micro modular reactors and clean energy solutions, positioning itself as a key player in the North American advanced reactor market [1][14] - The KRONOS MMR is a high-temperature, gas-cooled microreactor designed for modular deployment, capable of powering large industrial campuses and data centers [7][8] - The collaboration with BaRupOn is seen as a strategic opportunity to address the growing energy needs of high-energy-intensive sectors, particularly in the context of AI and data centers [4][8] Industry Context - The demand for electricity in the tech industry, especially for high-performance computing and data centers, is expected to double within the decade, creating a need for reliable, emission-free power sources [8][21] - The LAMP hub is designed to support advanced manufacturing and AI data centers, highlighting the intersection of energy development and technological innovation [6][13] - The feasibility study represents a significant milestone in NANO Nuclear's roadmap for commercial deployment and could lead to further multi-reactor agreements across the U.S. [11]